AT

AtriCure, Inc.

ATRCHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Jul 17, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$534.5M
+14.9% YoY
Net Income
-$44.7M
-46.8% YoY
EBITDA
$16.2M
+187.7% YoY
Free Cash Flow
$41.1M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 73.3, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 78.2, above 70, stock may be overbought
About AtriCure, Inc.

Part of the healthcare sector, AtriCure, Inc. (ATRC) is listed under Medical Instruments & Supplies. With a market capitalization of $1.80B, it sits in small-cap territory. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.

Key stats
Market Cap$1.80B
Fwd P/E102.15
EPS$-0.10
Beta1.25
52W Change+19.7%
ROE-1.0%
Analysis

The balance sheet looks solid with $146.2M in cash comfortably exceeding the $74.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $41.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -1.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $330.4M (2022) to $534.5M (2025), reflecting a 62% increase over the period.

Investors considering AtriCure, Inc. should weigh the typical risks associated with ATRC's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AtriCure, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms